A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Progression-free Survival
研究概览
简要总结
This study is for patients with metastatic colorectal cancer who have not been treated with chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and Sunitinib can be used together to improve progression-free survival in colorectal cancer.
All patients will take two medicines (Sunitinib and Capecitabine) by mouth every day until their cancer gets worse.
详细描述
This is a single-center, open-label, one-arm study. Patients will be stratified by prior adjuvant therapy and ECOG performance status at study entry.
In this study, we propose to obtain PET scans at baseline, 2 weeks, 8 weeks and 24 weeks from the initiation of treatment. Response at 2 weeks, 8 weeks and 24 weeks will be correlated to progression-free survival, overall survival and response according to RECIST criteria.
We will collect plasma and urine samples from enrolled patients before and four weeks after sunitinib treatment. The samples will be analyzed and results correlated with patient clinical outcomes in order to explore the underlying mechanism of sunitinib induced hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed, newly diagnosed metastatic colorectal cancer
- •Measurable or evaluable disease in which surgical resection with curative intent is not possible
- •No adjuvant chemotherapy within 6 months of enrollment
- •No prior sunitinib or other receptor tyrosine kinase inhibitors
- •18 years of age or greater
- •Anticipated survival of at least 6 months
- •Ambulatory with an ECOG performance status of 0 or 1 and able to maintain weight
- •Normal organ and marrow function
- •Must agree to avoid pregnancy or fathering a child through out study participation
- •Ability to understand and willingness to sign a written informed consent document
排除标准
- •Chemotherapy or radiotherapy within 6 months of enrollment
- •Receiving any other investigational agents
- •Known untreated brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis
- •Not able to ingest oral medications with normal absorption from the GI tract
- •Uncontrolled hypertension
- •History of severe/unstable angina, heart attack, congestive heart failure, transient ischemic attack, or stroke within 6 months of enrollment
- •Cardiac dysrhythmias
- •History of clinically significant bleeding within the past 6 months, including gross hemoptysis or hematuria, or underlying coagulopathy
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study enrollment
- •Current treatment with therapeutic doses of coumadin
- •Concurrent malignancy other than colorectal cancer
- •Known dihydropyrimidine dehydrogenase deficiency
- •Uncontrolled intercurrent illness including ongoing or active infection or psychiatric illness that would limit compliance with study requirements.
- •Pregnant and nursing women
研究组 & 干预措施
sunitinib and cepecitabine
Administration of sunitinib and capecitabine
干预措施: sunitinib and capecitabine (Drug)
结局指标
主要结局
Progression-free Survival
时间窗: 36 months
Progression-free survival (PFS) will be measured as the number of months between each patient's enrollment and his/her date of progression or date of death.
次要结局
未报告次要终点